Amaç: Çölyak hastal›¤› taramas›nda, anti-gliadin immunglobulin G ve A antikorlar›n›n kullan›m›, doku transglutaminaz ve endomisyal antikorlar›n daha yüksek olan duyarl›l›k ve özgüllü¤ü nedeniyle giderek azalmaktad›r. Kan›tlanm›fl ve muhtemel çölyak hastal›¤› olgular›nda, yüksek anti-gliadin immunglobulin A de¤erleri daha ciddi mukozal hasarla iliflkilidir. Çal›flman›n amac›, anti-gliadin immunglob
INTRODUCTION
Celiac disease (CD) may present with both gastrointestinal and non-gastrointestinal manifestations, including symptoms such as chronic abdominal pain, constipation, vomiting, short stature, or unexplained anemia (1) . The diagnosis of CD requires evaluation of clinical symptoms, serologic studies, and intestinal biopsies (1) . One of the challenges in the diagnosis of CD is utilizing the serologic studies available as a noninvasive screening method to determine which patients require confirmatory testing with small bowel biopsy as a gold standard investigation. The use of anti-gliadin antibodies immunoglobulin G and A (AGA IgG and IgA) for CD screening has decreased due to the higher specificity and sensitivity of tissue transglutaminase and endomysial antibodies (TTG and EMA IgA) (1) . Our aim was to determine if AGA IgA has any clinical importance in diagnosing CD in children who have chronic gastrointestinal symptoms.
MATERIALS AND METHODS
Children with a chronic history of vomiting, diarrhea, abdominal pain, and other gastrointestinal symptoms were evaluated for CD in the outpatient clinic of West Virginia University Hospitals. TTG IgA and AGA IgG and IgA in serum were determined by ELISA test, and EMA IgA was determined by indirect immunofluorescence. Some children with isolated positive AGA IgA were further evaluated by proximal gastrointestinal biopsies. The number of small bowel biopsies was a minimum of four specimens from both the proximal and distal duodenum and/or jejunum. The classic pathology changes of CD in the small bowel are categorized by the Marsh classification (1) as Marsh type 0, or preinfiltrative stage with normal mucosa; type 1, or increased number of intraepithelial lymphocytes, usually exceeding 20 per 100 enterocytes; type 2, or proliferation of the crypts of Lieberkühn; type 3, or partial (3a), subtotal (3b), or complete/total villous atrophy (3c); and type 4, or hypoplasia of the small bowel architecture (total villous atrophy with crypt hyperplasia). Although HLA DQ 2 and 8 testing is not a routine test, it is performed to evaluate a tendency harboring CD in suspected CD cases (1) .
Outpatient records of these children with a chronic history of gastrointestinal symptoms were reviewed after internal review boards at West Virginia University School of Medicine approved the study.
RESULTS
Sixteen children (8 males, 8 females; mean age: 9.7 years) had positive AGA IgA but negative TTG and EMA IgA antibodies. Vomiting, chronic intermittent diarrhea, recurrent abdominal pain, and chronic constipation were presenting symptoms in 6, 8, 13, and 4 of our patients, respectively. None had a history of steatorrhea or fat malabsorption. None had IgA deficiency. Only Patient 5 had a family history of CD. Thirteen underwent an upper endoscopy with multiple small bowel biopsies. Two patients had villous atrophy (Marsh 3a) consistent with a diagnosis of CD. Serum AGA IgA titers were significantly higher in patients who had Marsh histologic type 3a (Patients 1 and 2) as compared to those with type 0 (Patients 3-16) with the cut-off above 70 Units. Mean AGA IgA titers in type 3a vs. type 0 were 94.5 Units (70.0-119.0) vs. 31.5 Units (22.0-60.0) (Mann-Whitney test = 0.00, p=0.017). HLA DQ 2 and 8 testing was performed in only 6 patients due to insurance limitation, and 3 were positive (Table 1) .
Characteristics n=16
Age ( Clinical data in all patients are summarized in (1) . Serum AGA IgG titers were significant in both groups with Marsh histologic type 0 and 3a. This phenomenon has been reported in the era prior to the use of the more specific and sensitive antibody testing (EMA and TTG IgA), but the statistical power is still very low in this study (2) . Juto et al. (2) reported that elevated serum level of AGA IgA was strongly correlated with villous atrophy and was seen in infants younger than 3 years of age. The sole appearance of conventional AGA IgA in most children with gastrointestinal symptoms may be interpreted as a non-specific immunomodulation phenomenon (3).
Despite the higher sensitivity and specificity of TTG and EMA IgA and the NASPGHAN recommendation to use TTG IgA as the sole CD screening test, AGA IgA testing has been included in a part of CD serology as a screening panel by primary pediatricians and gastroenterologists (1). The anti-gliadin IgA and IgG tests are based on a sandwich enzyme immunoassay (ELISA) utilizing a horseradish peroxidase conjugated detection antibody. The sensitivity and specificity of anti-gliadin immunoglobulin testing has been shown to be inferior to that of TTG and EMA testing except for being slightly higher when using in treated celiac patients (1). Higher titers of AGA IgA may have more clinical significance in children with high index of suspicion for CD (4) . In a study by Bonamico et al. (5) , it was suggested that even low titers of AGA IgA in non-celiac patients may be an indication of increased intestinal permeability to macromolecules. In those patients with probable or proven CD, higher levels of AGA IgA of more than 70 Units/ml exhibit more severe mucosal damage in the small intestine (3). AGA IgA appeared to be a good indicator of the immune reaction in the small intestine triggered by gluten (2, 6, 7) . The extent of elevated AGA IgA in combination with a clinical history may be valuable in discerning which patients should undergo upper endoscopy for biopsies. Therefore, it is reasonable to infer that its levels correlate to some extent with mucosal injury. In this study, we cannot conclude that having positive and/or high titers of AGA IgA is sufficient for the diagnosis of CD.
Recently, the identification of specific B-cell epitopes on the gliadin molecule and the use of specific, synthetic, and conformationally intact B cells epitopes increasingly improved the development of the new test, Deamidated Gliadin Peptide (DGP) (8) . The selective deamidation of gliadin peptide is a process in which amino acid glutamine is converted to glutamic acid in the small intestine after gluten ingestion by the enzyme TTG (8) , and it immensely increases the gliadin peptide antigenicity and the sensitivity of DGP antibody assays or DP-AGA IgA and IgG (9) . Kaukinen (4) found that all antibody levels declined in line with mucosal recovery with a gluten-free diet. The DP-AGA antibody test interestingly was positive in six of the nine cases with small bowel mucosal damage persisting on a gluten-free diet, whereas positive TTG IgA was detected in only two cases and positive EMA IgA in none. The sensitivity and specificity are 91% and 98%, respectively (4). Unfortunately, none of our patients had residual serum stored in the laboratory to confirm the diagnosis with this test, but the patients were informed to follow up with their primary physicians for further evaluation if clinical symptoms of CD manifested later, including repeating all CD serology tests and upper endoscopy with small bowel biopsies.
In conclusion, higher levels of AGA IgA may have more clinical significance in children with a high index of suspicion for CD. The authors believe that some of these patients who have gastrointestinal symptoms with isolated AGA IgA should be followed, since the negative results of more specific antibodies like TTG IgA or EMA IgA could be falsely negative. Further immunopathogenic study from the small bowel biopsy to detect an early phase of CD might elucidate this phenomenon in this group of patients. The use of DP-AGA IgA in conjunction with TTG and EMA IgA could provide a more sensitive screening test for further evaluation for the diagnosis of CD.
